Ovarian cancer is the main cause of death from gynecological cancer in the world.
Nearly 70–80 % of patients are diagnosed in advanced stages, eg. FIGO stage III
–IV. Based on current standard frontline therapies, recurrences during follow-up
are very common, which determines a poor overall survival rates in the long term .
The new therapeutic approach should be developed.
To evaluate the clinical efficacy and perioperative safety of cytoreductive
surgery (CRS) in conjunction with hyperthermic intraperitonealchemotherapy (HIPEC)
for treating patients with stage IIIc ovarian cancer.
A total of 48 stage IIIc ovarian cancer patients were divided into the CRS group,
namely, Group One (n=24, CRS and systemic adjuvant chemotherapy) and the CRS +
HIPEC group, namely, Group Two (n=24, CRS+HIPEC and systemic adjuvant
chemotherapy). Completeness of cytoreduction (CCR) was evaluated and recorded
during the interventions. The primary end point was overall survival (OS) and the
second end points were serious adverse events (SAE).
Patients' clinicopathologic characteristics, peritoneal carcinomatosis index, and
completeness of cytoreduction therapy were well balanced and comparable between
the two groups. The median follow-up was 32.0 months (10.5 to 95.9 months) in
Group One and 41.9 months (6.5 to 110.0 months)in Group Two. The median OS was
18.27 months (95%CI, 10.15-26.40 months) in Group One and 39.29 months (95%CI,
29.96-48.61 months)in Group Two (P= 0.007). Within 30 days after the surgery,
SAE occurred in 3 of the 24 patients in Group One, and 7 of the 24 patients in
Group Two (P= 0.155). Multivariate analysis revealed that HIPEC, CC0-1 score, and
chemotherapy over six cycles were the independent factors for OS improvement.
The CRS+HIPEC method improves the OS of stage IIIc ovarian cancer patients ,
suggesting an acceptable safety.